4D Molecular Therapeutics Inc (NAS:FDMT)
$ 25.15 0 (0%) Market Cap: 1.30 Bil Enterprise Value: 788.60 Mil PE Ratio: 0 PB Ratio: 2.14 GF Score: 57/100

4D Molecular Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript

Jun 12, 2023 / 09:00PM GMT
Release Date Price: $22.94 (+4.42%)
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Good afternoon, everyone. Thanks for joining us. I'm Salveen Richter, biotechnology analyst at Goldman Sachs, and really pleased to have the 4D Molecular Therapeutics team with us. So maybe to start here, David. I'd have you just introduce the company kind of the situation that's played out through IPO until now with regard to the directed evolution platform, the disease verticals and where we've seen the progress play out across the programs to date.

David H. Kirn
4D Molecular Therapeutics, Inc. - Co-Founder, CEO & Director

Perfect. Well, thanks for having us here today. We're pleased to be here. I'm Dave Kirn, Co-Founder and CEO and this is [Julian Pay] , our Head of Investor Relations. So we're thrilled to be here. So 4D Molecular Therapeutics is a next-generation gene therapy company that's built on the power of the directed evolution platform to invent customized AV delivery vectors for any tissue in the body essentially.

And so what this allows us to do is have best

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot